Johnston Island - Press Releases

Now Joint Commission Accredited, Haven of Hope Provides Specialized Care for Eating Disorders and Trauma

FREEHOLD, N.J., Feb. 12, 2025 /PRNewswire/ -- January 18, 2025, marks the 20th anniversary of the incorporation of the Society for the Prevention of Teen Suicide (SPTS), a milestone that highlights two decades of dedicated efforts to empower communities, educate youth and adults, and save lives. Since its founding in 2005, SPTS has transformed from a grassroots initiative into a nationally recognized leader in youth mental health and suicide prevention.

MEMPHIS, Tenn., Feb. 12, 2025 /PRNewswire/ --Varsity Spirit - a division of Varsity Brands and a global leader in cheerleading, dance team and band apparel, camps and competitions, and yearbook - is pleased to announce the new champions named at the 2025 National High School Cheerleading Championship (NHSCC) that took place on February 7 - 10, 2025, at the ESPN Wide World of Sports Complex at The Walt Disney World Resort.

MEMPHIS, Tenn., Feb. 12, 2025 /PRNewswire/ --For many people, Valentine's Day has expanded its significance to include the celebration of friendship, helping those without romantic relationships feel included and loved. But, particularly for children and teens without strong friendships or a romantic relationship, the holiday can feel especially isolating.

Investment of $135,000 in First 30x30 Canada program contributes to conservation commitments

Letter congratulates new VA Secretary and offers solutions to addressing important healthcare needs

2025212 // -- FirstradeBlue Ocean TechnologiesBlue Ocean ATSFirstrade

2025212 // -- FirstradeBlue Ocean TechnologiesBlue Ocean ATSFirstrade

ALPHARETTA, Ga., Feb. 12, 2025 /PRNewswire/ -- Chroma Early Learning Academy, a leading provider of high-quality early childhood education, is proud to announce the opening of its 12th location in the Metro Atlanta area at 200 River Green Avenue, Canton, GA. This expansion supports Chroma's mission to deliver high-quality learning experiences to more families across the region.

IZERVAY dosing approved beyond 12 months

InterCure Logo (PRNewsfoto/InterCure Ltd.)

Highlights:

CHANDLER, Ariz., Feb. 12, 2025 /PRNewswire/ --Embark Behavioral Health, a leader in youth and young adult mental health care, is reaffirming its commitment to creating joy and healing generations. Under the leadership of Scott Filion, CEO, and Dr. Sharnell Myles, Psy.D., Chief Clinical Officer, the company is fortifying its mission through a revitalized clinical leadership team and expanding their current services to offer integrated mental health.

OMAHA, Neb., Feb. 12, 2025 /PRNewswire/ -- IHS, LLC., a leading business acquisitions and management firm, along with its physician partners, proudly announces the successful acquisition of BC Healthcare, a distinguished specialty medical practice recognized for its advanced healthcare services. This strategic acquisition marks a significant milestone in IHS, LLC.'s commitment to expanding high-quality, patient-centered care and elevating healthcare standards in Omaha, Nebraska, and beyond.

PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ --Palindrome Technologies has been recognized as an official testing facility for the IEEE Medical Device Cybersecurity Certification Program, positioning the company at the forefront of medical device security. This certification program, launched in 2023 by the IEEE 2621 Conformity Assessment Committee (CAC), offers a comprehensive evaluation process tailored specifically for medical devices in an increasingly connected healthcare landscape.

HONG KONG, Feb. 12, 2025 /PRNewswire/ --Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed PD-1/CTLA-4 bispecific antibody, cadonilimab. This study is evaluating the efficacy of cadonilimab compared to sugemalimab (PD-L1) as a consolidation therapy for patients with locally advanced, non-resectable, non-small cell lung cancer (NSCLC) who have not experienced disease progression following concurrent or sequential chemoradiotherapy.

NEW YORK, LONDON, MNCHEN und NEU-DELHI, 13. Februar 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG), gibt die Ernennung von Dr. Massimo Cristofanilli, MD, zum strategischen Berater bekannt. DCG ist ein weltweit fhrendes Unternehmen im Bereich der nicht-invasiven Krebsdiagnostik. Mit diesem Schritt unterstreicht DCG sein Engagement fr die Weiterentwicklung der Krebsfrherkennung und Przisionsmedizin.

CHENGDU, China, Feb. 12, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025,Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd "Kelun-Biotech" will present efficacy and safety results from the Phase 1/2 KL264-01/MK-2870-001 study (NCT04152499) of its anti-TROP2ADC sacituzumab tirumotecan (sac-TMT, formerly SKB-264/MK-2870) as monotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (UC) who progressed on or after prior anti-cancer therapies. These findings will be presented in a poster session on February 14, 2025, local time (Abstract #796).

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).

TOKYO, Feb. 13, 2025 /PRNewswire/ --Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been dosed atKeio University Hospital. RV-001 utilizes adeno-associated virus (AAV) vectors to deliver a unique functional gene encoding "Chimeric Rhodopsin", a light-driven G-protein activation mechanism to re-establish light activation in retinal interneurons. The goal is to expand light sensitivity to retinal interneurons via an intravitreal injection of RV-001. This milestone marks the initiation of the world's first clinical trial of optogenetic gene therapy, which leverages a proprietary "Chimeric Rhodopsin" for patients with retinitis pigmentosa (RP). "Over 2 million people worldwide suffer photoreceptor loss in retinitis pigmentosa, resulting in severe vision loss and eventual blindness" said, CEO and Ophthalmologist Yusaku Katada, MD, PhD. "Our "chimeric rhodopsin" approach has broad potential to alter light sensitivity across multiple subtypes of RP patients.[1] We are continuing to advance the Phase I/II trial to assess safety, light-activation and light-sensitivity in these patients, post-administration of our lead gene therapy product RV-001."

VADUZ, Liechtenstein, Feb. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.S. FDA has completed its review of the PMA Module 2 submission and provided its feedback, in which the company sees no barrier for responding.

SHANGHAI and HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that XPOVIO (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM) who have received at least two prior therapies, has been approved for reimbursement in Taiwan. Starting from March 1, 2025, XPOVIO will be officially included in the NHI drug reimbursement scheme.

HUNTINGTON BEACH, Calif., Feb. 12, 2025 /PRNewswire/ -- Karman Holdings Inc. ("Karman" or the "Company"), a company specializing in the upfront design, testing, manufacturing, and sale of mission-critical systems for existing and emerging missile and defense, and space programs, today announced the pricing of its initial public offering of 23,000,000 shares of its common stock at a public offering price of $22.00 per share (the "Common Stock"). The offering consists of 8,421,053 shares of Common Stock offered by Karman and 14,578,947 shares of Common Stock to be sold by certain of Karman's existing stockholders (the "Selling Stockholders"). Karman will not receive any proceeds from the sale of Common Stock by the Selling Stockholders. The shares of Karman's Common Stock are expected to begin tradingontheNewYorkStock Exchangeunderthetickersymbol "KRMN"onFebruary 13, 2025, and the offering is expected to close on February 14, 2025, subject to customary closing conditions.

The accomplished global business executive will oversee the firm's strategic growth initiatives for the Asia-Pacific region.

Kojamo plc Stock Exchange Release, 13 February 2025 at 8:30 a.m. EET